Literature DB >> 8321214

Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant.

F S Vassbotn1, M Andersson, B Westermark, C H Heldin, A Ostman.   

Abstract

A non-receptor-binding mutant of the platelet-derived growth factor (PDGF) A chain, PDGF-0, was generated by exchanging 7 amino acids in the sequence. The mutant chains formed dimers that were similar to wild-type PDGF-AA with regard to stability and rate of processing to the mature 30-kDa secreted forms. Moreover, the mutant chains formed disulfide-bonded heterodimers with the PDGF B chain in NIH 3T3 cells heterodimer underwent the same processing and secretion as PDGF-AB. Transfection of c-sis-expressing 3T3 cells with PDGF-0 significantly inhibited the transformed phenotype of these cells, as determined by the following criteria. (i) Compared with PDGF-0-negative clones, PDGF-0-producing clones showed a reverted morphology. (ii) Clones producing PDGF-0 grew more slowly than PDGF-0-negative clones, with a fivefold difference in cell number after 14 days in culture. (iii) The expression of PDGF-0 completely inhibited the ability of the c-sis-expressing 3T3 cells to form colonies in soft agar; this inhibition was overcome by the addition of recombinant PDGF-BB to the culture medium, showing that the lack of colony formation of these cells was not due to a general unresponsiveness to PDGF. The specific expression of a PDGF-0/PDGF wild-type heterodimer in COS cells revealed that the affinity of the mutant heterodimer for the PDGF alpha receptor was decreased by approximately 50-fold compared with that of PDGF-AA. Thus, we show that a non-receptor-binding PDGF A-chain mutant neutralizes in a trans-dominant manner the autocrine transforming potential of the c-sis/PDGF B chain by forming low-affinity heterodimers with wild-type PDGF chains. This method of specifically antagonizing the effect of PDGF may be useful in investigations of the role of PDGF in normal and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321214      PMCID: PMC359956          DOI: 10.1128/mcb.13.7.4066-4076.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  57 in total

1.  Role of alpha beta receptor heterodimer formation in beta platelet-derived growth factor (PDGF) receptor activation by PDGF-AB.

Authors:  M A Heidaran; J H Pierce; J C Yu; D Lombardi; J E Artrip; T P Fleming; A Thomason; S A Aaronson
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

2.  Use of an antiserum against phosphotyrosine for the identification of phosphorylated components in human fibroblasts stimulated by platelet-derived growth factor.

Authors:  B Ek; C H Heldin
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

3.  Demonstration of an antibody against platelet-derived growth factor.

Authors:  C H Heldin; B Westermark; A Wasteson
Journal:  Exp Cell Res       Date:  1981-12       Impact factor: 3.905

4.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Authors:  D Maglione; V Guerriero; G Viglietto; P Delli-Bovi; M G Persico
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

5.  Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF.

Authors:  A Smits; M Kato; B Westermark; M Nistér; C H Heldin; K Funa
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

6.  Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors.

Authors:  J S Huang; S S Huang; T F Deuel
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

7.  Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet-derived growth factor receptors.

Authors:  J S Garrett; S R Coughlin; H L Niman; P M Tremble; G M Giels; L T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

8.  Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus.

Authors:  A Johnsson; C Betsholtz; C H Heldin; B Westermark
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

9.  Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor.

Authors:  R F Doolittle; M W Hunkapiller; L E Hood; S G Devare; K C Robbins; S A Aaronson; H N Antoniades
Journal:  Science       Date:  1983-07-15       Impact factor: 47.728

10.  Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus.

Authors:  M D Waterfield; G T Scrace; N Whittle; P Stroobant; A Johnsson; A Wasteson; B Westermark; C H Heldin; J S Huang; T F Deuel
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

View more
  9 in total

1.  Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.

Authors:  S Y Cheng; H J Huang; M Nagane; X D Ji; D Wang; C C Shih; W Arap; C M Huang; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

2.  Platelet-derived growth factor-dependent association of the GTPase-activating protein of Ras and Src.

Authors:  T K Schlesinger; K A Demali; G L Johnson; A Kazlauskas
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.

Authors:  G Siemeister; M Schirner; P Reusch; B Barleon; D Marmé; G Martiny-Baron
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation.

Authors:  C E Bazenet; J A Gelderloos; A Kazlauskas
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

5.  Growth factor receptors signaling in glioblastoma cells: therapeutic implications.

Authors:  Mia Carapancea; Oana Alexandru; Ani S Fetea; Laura Dragutescu; Juan Castro; Ada Georgescu; A Popa-Wagner; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2008-11-30       Impact factor: 4.130

6.  A dominant-negative mutant of the platelet-derived growth factor A-chain increases survival of hamsters implanted intracerebrally with the highly invasive CxT24-neo3 glioblastoma cell.

Authors:  D M Kaetzel; J D Reid; N Pedigo; S G Zimmer; E R Boghaert
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

7.  Loop III region of platelet-derived growth factor (PDGF) B-chain mediates binding to PDGF receptors and heparin.

Authors:  D Schilling; J D Reid IV; A Hujer; D Morgan; E Demoll; P Bummer; R A Fenstermaker; D M Kaetzel
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

Review 8.  Gene therapy for carcinoma of the breast: Genetic ablation strategies.

Authors:  D T Curiel
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

9.  Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells.

Authors:  H Takeuchi; T Kanzawa; Y Kondo; S Kondo
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.